Purity
>95%, by SDS-PAGE with silver staining
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by the ability of the immobilized protein to support the adhesion of EOMA mouse endothelial cells. The ED 50 for this effect is 0.5-2.5 μg/mL. Measured by its ability to agglutinate human red blood cells. Hadari, Y.R. et al. (2000) J. Cell Sci. 113:2385. The ED 50 for this effect is 2.5-12.5 μg/mL.
Source
Human embryonic kidney cell, HEK293-derived Ser2-Glu130
Accession #
N-terminal Sequence
AnalysisSer2
Predicted Molecular Mass
15 kDa
SDS-PAGE
12-14 kDa, reducing conditions
8579-GA |
| |
Formulation Lyophilized from a 0.2 μm filtered solution in MOPS, NaCl, EDTA, DTT and Trehalose. | ||
Reconstitution Reconstitute at 400 μg/mL in water. | ||
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: Galectin-2
Galectin-2 is an approximately 14 kDa, homodimeric carbohydrate-binding protein of the S-type lectin family (1, 2). Like other prototype Galectins, Galectin-2 consists of a single carbohydrate-recognition domain (CRD) (3). Mouse Galectin-2 shares 86% and 66% amino acid sequence identity with rat and human Galectin-2, respectively. Galectin-2 is primarily expressed in the digestive tract and skin of mice (4-6). It can be S-nitrosylated with S-nitrosoglutathione in mouse gastric mucosa (7).
S-nitrosylation prevents Galectin-2 inactivation by hydrogen peroxide, suggesting that this modification protects Galectin-2 function against oxidative stress (8). Galectin-2 appears to have a role in immune responses. Galectin-2 mRNA and protein levels are down-regulated following infection with H. felis (9). Additionally, Galectin-2 treatment has been shown to reduce MHC class I-restricted immune responses and ameliorate acute and chronic experimental colitis in mice by inducing apoptosis of T cells (6, 10). Galectin-2 may also play a role in cancer since circulating levels of human Galectin-2 are elevated in colon and breast cancer patients (11).
References:
Hokama, A. et al. (2008) World J. Gastroenterol. 14:5133.
Barondes, S.H. et al. (1994) Cell 76:597.
Hirabayashi, J. and K. Kasai (1993) Glycobiology 3:297.
Nio, J. et al. (2005) J. Histochem. Cytochem. 53:1323.
Nio-Kobayashi, J. et al. (2009) J. Histochem. Cytochem. 57:41.
Loser, K. et al. (2009) J. Immunol. 182:5419.
Ohtake, K. et al. (2009) J. Proteomics 72:750.
Tamura, M. et al. (2015) Biochem. Biophys. Res. Commun. 457:712.
Takaishi, S. and T.C. Wang (2007) Cancer Sci. 98:284.
Paclik, D. et al. (2008) J. Mol. Med. 86:1395.
Chen, C. et al. (2014) Br. J. Cancer 110:741.
Entrez Gene IDs:
3957 (Human); 107753 (Mouse); 171134 (Rat)
Alternate Names:
Beta-galactoside-binding lectin L-14-II; GAL2; Gal-2; galectin 2; Galectin2; Galectin-2; HL14gal-2; Lactose-binding lectin 2; lectin, galactoside-binding, soluble, 2; LGALS2; MGC75071; S-Lac lectin 2
